Marie Oertel
Marie Oertel
Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Search for other papers by Marie Oertel in
Google Scholar
PubMed
Search for other papers by Marie Oertel in
Google Scholar
PubMed
Christian G Ziegler
Christian G Ziegler
Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden, Dresden, Germany
Search for other papers by Christian G Ziegler in
Google Scholar
PubMed
Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden, Dresden, Germany
Search for other papers by Christian G Ziegler in
Google Scholar
PubMed
Michael Kohlhaas
Michael Kohlhaas
Comprehensive Heart Failure Center, Würzburg, Germany
Search for other papers by Michael Kohlhaas in
Google Scholar
PubMed
Search for other papers by Michael Kohlhaas in
Google Scholar
PubMed
Alexander Nickel
Alexander Nickel
Comprehensive Heart Failure Center, Würzburg, Germany
Search for other papers by Alexander Nickel in
Google Scholar
PubMed
Search for other papers by Alexander Nickel in
Google Scholar
PubMed
Simon Kloock
Simon Kloock
Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Search for other papers by Simon Kloock in
Google Scholar
PubMed
Search for other papers by Simon Kloock in
Google Scholar
PubMed
Christoph Maack
Christoph Maack
Comprehensive Heart Failure Center, Würzburg, Germany
Search for other papers by Christoph Maack in
Google Scholar
PubMed
Search for other papers by Christoph Maack in
Google Scholar
PubMed
Vasco Sequeira
Vasco Sequeira
Comprehensive Heart Failure Center, Würzburg, Germany
Search for other papers by Vasco Sequeira in
Google Scholar
PubMed
Search for other papers by Vasco Sequeira in
Google Scholar
PubMed
Martin Fassnacht
Martin Fassnacht
Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Ulrich Dischinger
Ulrich Dischinger
Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Comprehensive Heart Failure Center, Würzburg, Germany
Search for other papers by Ulrich Dischinger in
Google Scholar
PubMed
Comprehensive Heart Failure Center, Würzburg, Germany
Search for other papers by Ulrich Dischinger in
Google Scholar
PubMed
, 20 ). Long-acting GLP-1 receptor (GLP-1-R) agonists, e.g. semaglutide, are already in clinical use for the treatment of obesity. In adults with overweight or obesity and without diabetes mellitus, semaglutide leads to a mean weight loss of about 10
Jeppe Skov
Jeppe Skov
Department of Endocrinology and Internal Medicine, Novo Nordisk A/S, NNF center for Basic Metabolic Research, Department of Clinical Biochemistry, Department of Clinical Physiology and Molecular Imaging, Department of Clinical Medicine, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus, Denmark
Department of Endocrinology and Internal Medicine, Novo Nordisk A/S, NNF center for Basic Metabolic Research, Department of Clinical Biochemistry, Department of Clinical Physiology and Molecular Imaging, Department of Clinical Medicine, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus, Denmark
Search for other papers by Jeppe Skov in
Google Scholar
PubMed
Department of Endocrinology and Internal Medicine, Novo Nordisk A/S, NNF center for Basic Metabolic Research, Department of Clinical Biochemistry, Department of Clinical Physiology and Molecular Imaging, Department of Clinical Medicine, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus, Denmark
Search for other papers by Jeppe Skov in
Google Scholar
PubMed
Jens Juul Holst
Jens Juul Holst
Department of Endocrinology and Internal Medicine, Novo Nordisk A/S, NNF center for Basic Metabolic Research, Department of Clinical Biochemistry, Department of Clinical Physiology and Molecular Imaging, Department of Clinical Medicine, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus, Denmark
Search for other papers by Jens Juul Holst in
Google Scholar
PubMed
Search for other papers by Jens Juul Holst in
Google Scholar
PubMed
Jens Peter Gøtze
Jens Peter Gøtze
Department of Endocrinology and Internal Medicine, Novo Nordisk A/S, NNF center for Basic Metabolic Research, Department of Clinical Biochemistry, Department of Clinical Physiology and Molecular Imaging, Department of Clinical Medicine, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus, Denmark
Search for other papers by Jens Peter Gøtze in
Google Scholar
PubMed
Search for other papers by Jens Peter Gøtze in
Google Scholar
PubMed
Jørgen Frøkiær
Jørgen Frøkiær
Department of Endocrinology and Internal Medicine, Novo Nordisk A/S, NNF center for Basic Metabolic Research, Department of Clinical Biochemistry, Department of Clinical Physiology and Molecular Imaging, Department of Clinical Medicine, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus, Denmark
Department of Endocrinology and Internal Medicine, Novo Nordisk A/S, NNF center for Basic Metabolic Research, Department of Clinical Biochemistry, Department of Clinical Physiology and Molecular Imaging, Department of Clinical Medicine, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus, Denmark
Search for other papers by Jørgen Frøkiær in
Google Scholar
PubMed
Department of Endocrinology and Internal Medicine, Novo Nordisk A/S, NNF center for Basic Metabolic Research, Department of Clinical Biochemistry, Department of Clinical Physiology and Molecular Imaging, Department of Clinical Medicine, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus, Denmark
Search for other papers by Jørgen Frøkiær in
Google Scholar
PubMed
Jens Sandahl Christiansen
Jens Sandahl Christiansen
Department of Endocrinology and Internal Medicine, Novo Nordisk A/S, NNF center for Basic Metabolic Research, Department of Clinical Biochemistry, Department of Clinical Physiology and Molecular Imaging, Department of Clinical Medicine, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus, Denmark
Search for other papers by Jens Sandahl Christiansen in
Google Scholar
PubMed
Search for other papers by Jens Sandahl Christiansen in
Google Scholar
PubMed
Introduction Glucagon-like peptide-1 (GLP1) is a gut-derived incretin hormone with multiple actions in addition to control of glucose homeostasis (1) . Synthetic GLP1 receptor (GLP1R) agonists lower blood pressure in patients with type 2 diabetes
Christine Rode Andreasen
Christine Rode Andreasen
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Christine Rode Andreasen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Christine Rode Andreasen in
Google Scholar
PubMed
Andreas Andersen
Andreas Andersen
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Andreas Andersen in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Andreas Andersen in
Google Scholar
PubMed
Filip Krag Knop
Filip Krag Knop
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Filip Krag Knop in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Filip Krag Knop in
Google Scholar
PubMed
Tina Vilsbøll
Tina Vilsbøll
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
neurodegenerative disease models ( 6 ). Deduced from both preclinical and human studies, GLP-1 has extra-pancreatic effects in the gut, kidney, nervous system, heart and immune system ( Fig. 1 ) ( 2 ). Multiple GLP-1R agonists (GLP-1RAs) utilising the plasma glucose
L Ahlkvist
L Ahlkvist
Search for other papers by L Ahlkvist in
Google Scholar
PubMed
Search for other papers by L Ahlkvist in
Google Scholar
PubMed
K Brown
K Brown
Department of Clinical Sciences, GlaxoSmithKline, Biomedical Center, C11, Lund University, SE 22184 Lund, Sweden
Search for other papers by K Brown in
Google Scholar
PubMed
Search for other papers by K Brown in
Google Scholar
PubMed
B Ahrén
B Ahrén
Search for other papers by B Ahrén in
Google Scholar
PubMed
Search for other papers by B Ahrén in
Google Scholar
PubMed
groups. Acute effect of GPR119 activation in CD and HFD-fed mice To determine changes in intestinal GLP1 secretion in insulin resistance, a GPR119 agonist (GSK706A, 10 mg/kg) or vehicle was given orally before (−10 min) an oral liquid test meal to CD and
Giuseppe Lisco
Giuseppe Lisco
Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
Search for other papers by Giuseppe Lisco in
Google Scholar
PubMed
Search for other papers by Giuseppe Lisco in
Google Scholar
PubMed
Anna De Tullio
Anna De Tullio
Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
Search for other papers by Anna De Tullio in
Google Scholar
PubMed
Search for other papers by Anna De Tullio in
Google Scholar
PubMed
Olga Disoteo
Olga Disoteo
Diabetology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Search for other papers by Olga Disoteo in
Google Scholar
PubMed
Search for other papers by Olga Disoteo in
Google Scholar
PubMed
Giuseppina Piazzolla
Giuseppina Piazzolla
Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
Search for other papers by Giuseppina Piazzolla in
Google Scholar
PubMed
Search for other papers by Giuseppina Piazzolla in
Google Scholar
PubMed
Edoardo Guastamacchia
Edoardo Guastamacchia
Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
Search for other papers by Edoardo Guastamacchia in
Google Scholar
PubMed
Search for other papers by Edoardo Guastamacchia in
Google Scholar
PubMed
Carlo Sabbà
Carlo Sabbà
Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
Search for other papers by Carlo Sabbà in
Google Scholar
PubMed
Search for other papers by Carlo Sabbà in
Google Scholar
PubMed
Vincenzo De Geronimo
Vincenzo De Geronimo
Unit of Endocrinology, Policlinico Morgagni CCD, Catania, Italy
Search for other papers by Vincenzo De Geronimo in
Google Scholar
PubMed
Search for other papers by Vincenzo De Geronimo in
Google Scholar
PubMed
Enrico Papini
Enrico Papini
Department of Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy
Search for other papers by Enrico Papini in
Google Scholar
PubMed
Search for other papers by Enrico Papini in
Google Scholar
PubMed
Vincenzo Triggiani
Vincenzo Triggiani
Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
Search for other papers by Vincenzo Triggiani in
Google Scholar
PubMed
Search for other papers by Vincenzo Triggiani in
Google Scholar
PubMed
Background Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have relevant antihyperglycemic effects and provide significant improvement on diabetes-related outcomes such as overweight and obesity, cardiovascular and renal impairment, and
Svjatoslavs Kistkins
Svjatoslavs Kistkins
Pauls Stradiņš Clinical University Hospital, Riga, Latvia
Search for other papers by Svjatoslavs Kistkins in
Google Scholar
PubMed
Search for other papers by Svjatoslavs Kistkins in
Google Scholar
PubMed
Othmar Moser
Othmar Moser
Division of Exercise Physiology and Metabolism, Institute of Sport Science, University of Bayreuth, Bayreuth, Germany
Search for other papers by Othmar Moser in
Google Scholar
PubMed
Search for other papers by Othmar Moser in
Google Scholar
PubMed
Vitālijs Ankudovičs
Vitālijs Ankudovičs
Pauls Stradiņš Clinical University Hospital, Riga, Latvia
Search for other papers by Vitālijs Ankudovičs in
Google Scholar
PubMed
Search for other papers by Vitālijs Ankudovičs in
Google Scholar
PubMed
Dmitrijs Blizņuks
Dmitrijs Blizņuks
Institute of Smart Computing Technologies, Riga Technical University, Riga, Latvia
Search for other papers by Dmitrijs Blizņuks in
Google Scholar
PubMed
Search for other papers by Dmitrijs Blizņuks in
Google Scholar
PubMed
Timurs Mihailovs
Timurs Mihailovs
Institute of Smart Computing Technologies, Riga Technical University, Riga, Latvia
Search for other papers by Timurs Mihailovs in
Google Scholar
PubMed
Search for other papers by Timurs Mihailovs in
Google Scholar
PubMed
Sergejs Lobanovs
Sergejs Lobanovs
Pauls Stradiņš Clinical University Hospital, Riga, Latvia
Search for other papers by Sergejs Lobanovs in
Google Scholar
PubMed
Search for other papers by Sergejs Lobanovs in
Google Scholar
PubMed
Harald Sourij
Harald Sourij
Trials Unit for Interdisciplinary Metabolic Medicine, Division of Endocrinology and Diabetolgoy, Medical University of Graz, Graz, Austria
Search for other papers by Harald Sourij in
Google Scholar
PubMed
Search for other papers by Harald Sourij in
Google Scholar
PubMed
Andreas F H Pfeiffer
Andreas F H Pfeiffer
Department of Endocrinology and Metabolic Medicine, Campus Benjamin Franklin, Charité University Medicine, Hindenburgdamm, Berlin, Germany
Search for other papers by Andreas F H Pfeiffer in
Google Scholar
PubMed
Search for other papers by Andreas F H Pfeiffer in
Google Scholar
PubMed
Valdis Pīrāgs
Valdis Pīrāgs
Pauls Stradiņš Clinical University Hospital, Riga, Latvia
Faculty of Medicine, University of Latvia, Riga, Latvia
Search for other papers by Valdis Pīrāgs in
Google Scholar
PubMed
Faculty of Medicine, University of Latvia, Riga, Latvia
Search for other papers by Valdis Pīrāgs in
Google Scholar
PubMed
insulin sensitivity and beta-cell function and subsequently glycaemic control. GLP-1 receptor agonists and dual hormone therapies have exhibited promising outcomes in those with T2D and obesity. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has
Lili Liu
Lili Liu
Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Lili Liu in
Google Scholar
PubMed
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Lili Liu in
Google Scholar
PubMed
Zhuo Shao
Zhuo Shao
Department of General Surgery, Changhai Hospital, The Second Military Medical University, Shanghai, Shanghai, China
Search for other papers by Zhuo Shao in
Google Scholar
PubMed
Search for other papers by Zhuo Shao in
Google Scholar
PubMed
Ying Xia
Ying Xia
Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Ying Xia in
Google Scholar
PubMed
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Ying Xia in
Google Scholar
PubMed
Jiabi Qin
Jiabi Qin
Department of Epidemiology & Health Statistics, Xiangya School of Public Health, Central South University, Changsha, Hunan, China
Search for other papers by Jiabi Qin in
Google Scholar
PubMed
Search for other papers by Jiabi Qin in
Google Scholar
PubMed
Yang Xiao
Yang Xiao
Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Yang Xiao in
Google Scholar
PubMed
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Yang Xiao in
Google Scholar
PubMed
Zhiguang Zhou
Zhiguang Zhou
Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Zhiguang Zhou in
Google Scholar
PubMed
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Zhiguang Zhou in
Google Scholar
PubMed
Zubing Mei
Zubing Mei
Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Search for other papers by Zubing Mei in
Google Scholar
PubMed
Search for other papers by Zubing Mei in
Google Scholar
PubMed
. Incretin-based drugs, including glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase 4 (DPP-4) inhibitors, may offer an opportunity to avoid these side effects. Theoretically, GLP-1 RAs are structurally and functionally similar to
M Jensterle
M Jensterle
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia
Search for other papers by M Jensterle in
Google Scholar
PubMed
Search for other papers by M Jensterle in
Google Scholar
PubMed
A Podbregar
A Podbregar
University Rehabilitation Institute Republic of Slovenia, Ljubljana, Slovenia
Search for other papers by A Podbregar in
Google Scholar
PubMed
Search for other papers by A Podbregar in
Google Scholar
PubMed
K Goricar
K Goricar
University of Ljubljana, Faculty of Medicine, Institute of Biochemistry, Pharmacogenetics Laboratory, Ljubljana, Slovenia
Search for other papers by K Goricar in
Google Scholar
PubMed
Search for other papers by K Goricar in
Google Scholar
PubMed
N Gregoric
N Gregoric
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia
Search for other papers by N Gregoric in
Google Scholar
PubMed
Search for other papers by N Gregoric in
Google Scholar
PubMed
A Janez
A Janez
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia
Search for other papers by A Janez in
Google Scholar
PubMed
Search for other papers by A Janez in
Google Scholar
PubMed
not yet been addressed in a prospective clinical study. There was only one retrospective observational study reporting that adding long-acting GLP1 receptor agonist liraglutide to LSM, metformin and TRT boosted erectile function in obese men with type
Zhenyu Liu
Zhenyu Liu
Department of Clinical Medicine, Beijing Luhe Hospital, Capital Medical University, Tongzhou District, Beijing, China
Search for other papers by Zhenyu Liu in
Google Scholar
PubMed
Search for other papers by Zhenyu Liu in
Google Scholar
PubMed
Huixi Kong
Huixi Kong
Department of Clinical Medicine, Beijing Shijitan Hospital, Capital Medical University, Haidian District, Beijing, China
Search for other papers by Huixi Kong in
Google Scholar
PubMed
Search for other papers by Huixi Kong in
Google Scholar
PubMed
Baoyu Zhang
Baoyu Zhang
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Tongzhou District, Beijing, China
Search for other papers by Baoyu Zhang in
Google Scholar
PubMed
Search for other papers by Baoyu Zhang in
Google Scholar
PubMed
response to an acute acid load ( 36 ). Glucagon-like peptide-1 receptor agonists Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exert hypoglycemic effects by activating the GLP-1 receptor in a glucose concentration-dependent manner
Signe Frøssing
Signe Frøssing
Department of Internal Medicine, Center of Endocrinology and Metabolism, Herlev Gentofte Hospital, Copenhagen, Denmark
Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Signe Frøssing in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Signe Frøssing in
Google Scholar
PubMed
Malin Nylander
Malin Nylander
Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
Department of Obstetrics & Gynecology, Herlev Gentofte Hospital, Copenhagen, Denmark
Search for other papers by Malin Nylander in
Google Scholar
PubMed
Department of Obstetrics & Gynecology, Herlev Gentofte Hospital, Copenhagen, Denmark
Search for other papers by Malin Nylander in
Google Scholar
PubMed
Caroline Kistorp
Caroline Kistorp
Department of Internal Medicine, Center of Endocrinology and Metabolism, Herlev Gentofte Hospital, Copenhagen, Denmark
Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Caroline Kistorp in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Caroline Kistorp in
Google Scholar
PubMed
Sven O Skouby
Sven O Skouby
Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
Department of Obstetrics & Gynecology, Herlev Gentofte Hospital, Copenhagen, Denmark
Search for other papers by Sven O Skouby in
Google Scholar
PubMed
Department of Obstetrics & Gynecology, Herlev Gentofte Hospital, Copenhagen, Denmark
Search for other papers by Sven O Skouby in
Google Scholar
PubMed
Jens Faber
Jens Faber
Department of Internal Medicine, Center of Endocrinology and Metabolism, Herlev Gentofte Hospital, Copenhagen, Denmark
Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
agonists (GLP-1RA) were developed for treatment of hyperglycemia in T2D, but have additionally weight-reducing effect and have proven effective in smaller studies in women with PCOS ( 19 ). The LEADER study in high-risk patients with T2D reported that the
